Simulated Assessment of Pharmacokinetically Guided Dosing for Investigational Treatments of Pediatric Patients With Coronavirus Disease 2019.

ABSTRACT:

Importance

Children of all ages appear susceptible to severe acute respiratory syndrome coronavirus 2 infection. To support pediatric clinical studies for investigational treatments of coronavirus disease 2019 (COVID-19), pediatric-specific dosing is required.

Objective

To define pediatric-specific dosing regimens for hydroxychloroquine and remdesivir for COVID-19 treatment.

Design, setting, and participants

Pharmacokinetic modeling and simulation were used to extrapolate investigated adult dosages toward children (March 2020-April 2020). Physiologically based pharmacokinetic modeling was used to inform pediatric dosing for hydroxychloroquine. For remdesivir, pediatric dosages were derived using allometric-scaling with age-dependent exponents. Dosing simulations were

SUBMITTER: Maharaj AR 

PROVIDER: S-EPMC7275264 | biostudies-literature | 2020 Oct

REPOSITORIES: biostudies-literature